Antibiotics & Medicine History

Humanity has been fighting infections for longer than written history. Neanderthals may have applied birch bark pitch to wounds around 200,000 years ago, likely harnessing its antibacterial properties. ^[1] When researchers recreated Neanderthal birch tar in the lab, biological tests confirmed those antibacterial properties were real. ^[1] This is your VocaCast briefing on antibiotics for Wednesday, April 22.

We start with the crisis, then the breakthrough.

Before antibiotics arrived, infectious disease was the leading cause of death across industrialized nations. In 1900, infectious diseases caused one-third of all mortality in the United States, with pneumonia, tuberculosis, and diarrheal diseases claiming the most lives. ^[2] Average life expectancy at birth in the industrialized world stood at just 47 years. ^[3] For most of human history, a cut or infection meant serious risk of death — there was simply no reliable treatment.

Then came the turning point. Researchers had begun synthesizing antibacterial compounds decades before the breakthrough. Sulfa drugs revolutionized medicine in the 1930s, and the first antibiotic drug to cure syphilis was developed in the 1910s, earning its creator, Ehrlich, recognition as a father of chemotherapy. ^[4] But it was the cascade of agents starting in the 1940s — sulfonamides, penicillin, and streptomycin — that transformed everything. ^[5] The widespread use of these antibiotics in the 1950s and 1960s contributed to rapid increases in life expectancy and reduced surgical mortality. ^{[6] [5]} Antibiotics extended the average human lifespan by 23 years. ^[7] What began as desperate attempts to treat infection became one of medicine's greatest achievements.

The revolution began because the stakes of infection were unbearably high. Before antibiotics, 90 percent of children infected with meningitis did not survive. ^[8] Even simple surgeries and minor wounds were dangerous, with postoperative infections being common and often fatal. ^[9] The body had no chemical defense against bacterial invasion once an infection took hold. The introduction of penicillin changed that calculus entirely. Mortality for penicillin-sensitive causes of death fell by 0.3 per thousand relative to the mean prior to 1947, representing a 58 percent decline overall. ^[2] That shift meant families stopped losing children to treatable bacterial infections. It meant surgeons could operate without fear that the wound itself would kill the patient.

That safety opened doors that had been locked for centuries. The introduction of antibiotics enabled complex medical procedures such as surgeries, organ transplants, and chemotherapy, which rely on effective infection control. ^[10] Without antibacterial agents standing guard against secondary infections, none of these interventions would be possible.

That lifesaving power, however, faces an accelerating crisis. An opinion piece published on April 16, warned that big pharmaceutical companies were failing to tackle the greatest threat to modern medicine. ^[11] The problem is antimicrobial resistance, or AMR—the ability of bacteria and other microorganisms to survive drugs designed to kill them. The pipeline of new antibiotics has been dangerously thin. In the late 2000s and early 2010s, four new classes of antibiotics were introduced to clinical use following a 40-year period without new discoveries of antibacterial compounds. ^[12] That drought matters because bacteria don't stop evolving. AMR is driven by antibiotic misuse and overuse in human and animal health, and agriculture.

The same threat has been compared to a silent pandemic—one that could surpass other causes of mortality by 2050. ^[13] When patients skip doses, when livestock are given antibiotics to promote growth, when hospitals use broad-spectrum drugs as routine precaution—bacteria respond by developing resistance. The mechanisms are sophisticated: enzymatic degradation that inactivates drugs, target modification that changes where antibiotics bind, efflux pump activation that pumps drugs out of bacterial cells, reduced membrane permeability that blocks entry, and biofilm formation that shields colonies from treatment.

The human cost is staggering. Antimicrobial resistance is projected by WHO to cause approximately 10 million deaths annually by 2050, making it one of the top global public health threats. ^[14] The burden falls unevenly—the world's highest mortality rate from antimicrobial resistance infection is observed in Africa. ^[5] Beyond lives, the economic damage reshapes nations. AMR is predicted to reduce gross domestic product by 1.1 to 3 and three quarter percent by 2050, with potential losses ranging from 60 to 100 trillion dollars by the same year, particularly impacting developing countries. ^[15] Yet bacteria are engineering new defenses faster than we can respond.

Extended-spectrum β-lactamases, known as ESBLs, can inactivate a wide range of β-lactams—the foundational class of antibiotics—while carbapenemases target carbapenems, drugs reserved for the most serious infections. ^[16] This enzymatic diversification means bacteria aren't developing resistance to one drug; they're developing resistance across entire families.

To wrap up, controlling antimicrobial resistance requires a coordinated global effort that spans human medicine, agriculture, and environmental management. The One Health approach is crucial for addressing AMR, involving effective communication, education, training, and surveillance across human, animal, and environmental sectors. ^[17] This interconnected strategy recognizes that resistance doesn't stop at the edges of hospitals or farms—it moves through populations and ecosystems, so every sector must work in tandem. A comprehensive One Health strategy integrating artificial intelligence and rapid diagnostics is proposed to combat AMR and support sustainable development goals.